At Aptorum, we believe that by facilitating the development of medical innovations, particularly in those that able to meet current unmet medical needs and significantly improve clinical and surgical experience, is inevitable in advancing the quality of human life and patient care. With this vision, Mr. Ian Huen founded Aptorum, leveraging the region’s talented specialists and prosperous medical resources, to accelerate the evolution of potentially First-in-Class/Best-in-Class therapeutic and diagnostic innovations across a wide range of disease areas. By combining a broad project portfolio of preclinical stage novel medical innovations and multi-disciplinary human capital, Aptorum aims to become a world class player in the biopharmaceutical industry with emphasis in science, collaboration and entrepreneurship.
Facilitate life science innovations to tackle unmet medical needs
Assembled with Distinguished Industry and Academic Talents
Deep Portfolio and Strong Life Science Development Capabilities
Enthralling Market Potential and Growth Prospects
Miss sabrina khan: Chief Financial Officer
Miss Sabrina Khan is the Chief Financial Officer of Aptorum Group Limited. She leads the Company’s financial strategy and operations, as well as Investor Relations. She has extensive experience working at KPMG (Hong Kong) and Ernst & Young LLP (Hong Kong). She was a regional financial controller in Asia for St. James’s Place Wealth Management (Hong Kong), which St. James’s Place Wealth Management Group (LON: STJ) is a FTSE100 company.
Aptorum Group Limited’s Chief Financial Officer is Miss Sabrina Khan. She is in charge of the Company’s financial strategy, operations, and investor relations. She worked at KPMG (Hong Kong) and Ernst & Young LLP for a long time (Hong Kong). She worked for St. James’s Place Wealth Management (Hong Kong), which is part of the St. James’s Place Wealth Management Group (LON: STJ), a FTSE100 firm.
She was previously the senior financial manager of Neo Derm Group, a prominent medical aesthetics company in Asia, where she was in charge of finance and expansion in the PRC.She worked as the senior finance manager of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation , which was a subsidiary of Golden Meditech Holdings Limited , from August 2009 to May 2013, where she was responsible for NYSE listing filings, investor relations, and post-IPO reporting.
She assisted and liaised with investment banks on due diligence during her time at Global Cord Blood Corporation, where she was actively involved in the issuing of convertible bonds to Kohlberg Kravis Roberts and several merger and acquisition transactions. deal structuring, and also involved in commercial negotiation with respect to major contract terms.
Miss Khan qualified as certified public accountant and graduated with a BBA (Hons) in Accounting & Finance at The University of Hong Kong in 2003. She was qualified as an Advanced China Certified Taxation Consultant in 2015.
Website : http://www.aptorumgroup.com/
Industry : Biotechnology
Company size : 11-50 employees
Headquarters : London, England
Type : Public Company
Founded : 2010
Specialties : Biotechnology and Pharmaceutical
Sources and references : http://www.aptorumgroup.com/
Story Edited by : SwiftNLift Business Magazine Company